Fujian Shengdi Pharmaceutical Co., Ltd.

This phase 3 trial tests whether HRS9531 tablets can help overweight or obese adults lose weight over 52 weeks. About 425 participants will receive either the drug or a placebo. The study measures weight change and the proportion of people losing at least 5% of their body weight.

This early-stage study tests how the body processes HRS9531 tablets under different dosing conditions. It involves 100 healthy adults aged 18-55 with a BMI between 23 and 35. The goal is to measure drug levels and safety, not yet to treat weight or diabetes.

This clinical trial tests two experimental injections, HRS-4729 and HRS9531, in adults with metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition linked to obesity. The study involves 160 participants who receive either the drug or a placebo for 52 we…

This study tests an experimental injection called HRS-5635 in adults with chronic hepatitis B whose virus is already controlled by daily pills. The goal is to see if the injection can help the body clear the virus so patients can safely stop all hepatitis B medications. About 540…

This Phase 2 trial tests whether HRS9531 tablets can improve blood sugar control in people with type 2 diabetes who haven't achieved good control with lifestyle changes or metformin alone. About 240 participants will receive either the drug or a placebo for 20 weeks. The main goa…

This early-stage trial tests the safety of an investigational injection called HRS9531 in 48 Chinese adolescents aged 12 to 17 who are obese. Participants receive either the drug or a placebo, and researchers monitor side effects, drug levels in the blood, and changes in weight a…